Transfer of production of active pharmaceutical ingredients for generic drugs
First written in FY2017-Q1. 10 of 29 entries say "Restated". Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026AdvancedAnnual report
「Sales of both proprietary products and products manufactured by other companies were strong, resulting in higher net sales of pharmaceutical active ingredients.」
In addition to proprietary products, third-party products also sold well, broadening the drivers of higher API revenue. - FY2026-H1RestatedAnnual report
「API revenue increased because sales of proprietary products performed well.」
Higher API revenue driven by strong sales of proprietary products continues. - FY2025-H1AdvancedAnnual report
「API revenue increased because sales of proprietary products progressed smoothly.」
Smooth sales of proprietary products increased API revenue. - FY2024-Q3Lower API revenue due to changes in customer delivery schedulesAnnual report
「API revenue declined because changes in customers’ delivery schedules for proprietary products reduced sales volumes.」
Customers changed the delivery schedules for proprietary products, contributing to lower API sales volumes and revenue. - FY2024-Q2Higher API revenue due to strong demand for imported productsAnnual report
「API revenue increased because customer demand for imported products was strong.」
Whereas the previous quarter cited customers’ production-schedule changes for proprietary products, this quarter strong customer demand for imported products was cited as a factor behind higher API revenue. - FY2023AdvancedAnnual report
「In addition, at subsidiary Active Pharma Co., Ltd., steady progress was made toward commercializing the continuous-flow process for manufacturing APIs for pharmaceuticals, which offers advantages over conventional synthesis methods in efficiency, safety and environmental compatibility.」
Efforts in the API business centered on the Toyama-Yatsuo Plant have become more concrete, including expanding transactions for APIs for new drugs and long-listed products in addition to generics, and commercializing the continuous-flow process. - FY2023-Q3RestatedAnnual report
「API revenue declined because customers changed the production schedules for proprietary products.」
Customers’ changes to production schedules for proprietary products continue to contribute to lower API revenue. - FY2023-Q2Lower revenue due to customers changing production schedulesAnnual report
「API revenue declined because customers changed the production schedules for proprietary products.」
Customers changed the production schedules for proprietary products, contributing to lower API revenue. - FY2023-Q1Lower revenue due to customers changing production schedulesAnnual report
「API revenue declined because customers changed the production schedules for proprietary products.」
Customers’ changes to production schedules for proprietary products were again cited as a factor behind lower API revenue. - FY2022-Q3Lower API revenue due to supply chain disruptions and other factorsAnnual report
「API revenue declined due to the impact of adopting the revenue recognition accounting standard, supply chain disruptions in the generic drug industry and a large spot API supply contract in the same period of the previous year.」
While efforts to produce and sell APIs, centered on the Toyama-Yatsuo Plant, continued, revenue declined due to the revenue recognition accounting standard, supply chain disruptions in the generic drug industry and the absence of a large contract recorded in the same period of the previous year. - FY2022-Q2RestatedAnnual report
「Although proprietary products remained solid, API revenue declined because customer demand for imported products and merchandise decreased.」
Proprietary products remained solid, but lower customer demand for imported products and merchandise reduced overall API revenue. - FY2022-Q1Strong proprietary products; lower demand for imported products and other merchandiseAnnual report
「Although proprietary products performed well, API revenue declined because customer demand for imported products and merchandise decreased.」
Proprietary products performed well, but lower customer demand for imported products and merchandise reduced overall API revenue. - FY2021AdvancedAnnual report
「In addition, by leveraging the development center and small-scale synthesis building at the Toyama-Yatsuo Plant of our subsidiary Active Pharma Co., Ltd., completed in May last year, we will work to expand transactions involving APIs for new drugs and long-listed products.」
Following completion of the development center and small-scale synthesis building at the Toyama-Yatsuo Plant, the company has moved to the stage of using these facilities to expand transactions involving APIs for new drugs and long-listed products. - FY2021-Q3AdvancedAnnual report
「Revenue from APIs increased because the company’s proprietary products performed well.」
Strong performance by proprietary products increased API revenue. - FY2021-Q2RestatedAnnual report
「Operating profit was ¥523 million, down 31.6% year on year, mainly due to higher costs associated with the completion of the development center and small-scale synthesis building at the Toyama-Yatsuo Plant of the company’s subsidiary Active Pharma Co., Ltd. in May this year.」
Even after completion of the development center and small-scale synthesis building at the Toyama-Yatsuo Plant, the associated increase in costs continues to weigh on earnings in the chemicals-related business. - FY2021-Q1AdvancedAnnual report
「Operating profit was ¥168 million, down 33.9% year on year, mainly due to higher costs associated with the completion of the development center and small-scale synthesis building at the Toyama-Yatsuo Plant of the company’s subsidiary Active Pharma Co., Ltd. in May this year.」
The development center and small-scale synthesis building at the Toyama-Yatsuo Plant were completed in May. However, the associated increase in costs reduced earnings in the chemicals-related business. - FY2020-Q3Expansion of proprietary products and discontinuation of certain merchandiseAnnual report
「Although sales of proprietary products increased, API revenue declined because the company discontinued handling certain merchandise.」
Sales of proprietary products increased, but API revenue declined following the discontinuation of certain merchandise. - FY2020-Q2AdvancedAnnual report
「Revenue from APIs increased as sales of the company’s core proprietary products expanded.」
The company expanded sales of its core proprietary products, driving higher API revenue. - FY2019-Q3RaisedAnnual report
「With respect to APIs, in December 2018 we decided to increase the investment amount and revise the construction schedule for the facilities investment at the Toyama-Yatsuo Plant of our subsidiary Active Pharma Co., Ltd., announced in December 2017. Accordingly, in addition to APIs for generic drugs, we will also pursue the manufacture of APIs for new drugs and long-listed products.」
The company announced plans to increase investment and revise the construction schedule for the Toyama-Yatsuo Plant, while expanding its manufacturing scope from APIs for generic drugs to APIs for new drugs and long-listed products. - FY2019-Q2RestatedAnnual report
「Revenue from APIs increased as sales volumes of existing products, newly developed in-house products and other existing products rose.」
Sales volumes of existing products, newly developed proprietary products and existing merchandise continue to increase. - FY2019-Q1AdvancedAnnual report
「Revenue from APIs increased as sales volumes of existing products, newly developed products and other existing products rose. As a result, total revenue increased 10.2% year on year to ¥7,868 million. Operating income increased 70.8% to ¥303 million, reflecting higher gross profit from increased revenue and the successful promotion of continuous production at the Toyama Yatsuo Plant in API manufacturing.」
The successful promotion of continuous production at the Toyama Yatsuo Plant, together with higher sales volumes of existing products, newly developed products and other products, contributed to higher revenue and profit in the chemicals-related business. - FY2018-Q3RestatedAnnual report
「In API production, revenue declined despite progress in continuous production at the Toyama Yatsuo Plant and sales of newly developed and existing products, as well as higher demand for some existing products, due to the impact of pharmaceutical formulators moderating inventory building aimed at ensuring stable supply.」
Continuous production at the Toyama Yatsuo Plant and sales of newly developed and existing products continue to progress, but revenue declined due to the impact of moderated inventory building. - FY2018-Q2RestatedAnnual report
「In API production, we promoted continuous production at the Toyama Yatsuo Plant and advanced sales of newly developed products, but」
Continuous production at the Toyama Yatsuo Plant and sales of newly developed products continue to progress. - FY2018-Q1AdvancedAnnual report
「In API production, revenue increased despite some impact from pharmaceutical formulators moderating inventory building aimed at ensuring stable supply. We promoted continuous production at the Toyama Yatsuo Plant, benefited from higher demand for some products, and began full-scale sales of newly developed products.」
Revenue from API production increased as continuous production at the Toyama Yatsuo Plant progressed and full-scale sales of newly developed products began. - FY2017-Q3RestatedAnnual report
「In API production for generic drugs, production changed from the Tokyo Machida Plant to the Toyama Yatsuo Plant and progressed steadily. However, revenue declined as pharmaceutical formulators continued to moderate inventory building aimed at ensuring stable supply.」
Production changed from the Tokyo Machida Plant to the Toyama Yatsuo Plant and continues to progress steadily. - FY2017-Q2RestatedAnnual report
「In API production for generic drugs, production changed from the Tokyo Machida Plant to the Toyama Yatsuo Plant and progressed steadily. However, revenue declined as pharmaceutical formulators moderated inventory building aimed at ensuring stable supply.」
Production changed from the Tokyo Machida Plant to the Toyama Yatsuo Plant and continues to progress. - FY2017-Q1First statedAnnual report
「Production changed from the Tokyo Machida Plant to the Toyama Yatsuo Plant and progressed steadily, but」
The initiative to move API production from the Tokyo Machida Plant to the Toyama Yatsuo Plant is progressing.